These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36317687)

  • 1. Toward a broader concept of societal value: family spillovers in Alzheimer's disease.
    Park JY; Marcum ZA; Garrison LP
    Int J Technol Assess Health Care; 2021 Dec; 38(1):e7. PubMed ID: 36317687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.
    Lin PJ; D'Cruz B; Leech AA; Neumann PJ; Sanon Aigbogun M; Oberdhan D; Lavelle TA
    Pharmacoeconomics; 2019 Apr; 37(4):597-608. PubMed ID: 30903567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
    Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of caregiver costs included in cost-of-illness studies.
    Mattingly TJ; Diaz Fernandez V; Seo D; Melgar Castillo AI
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1051-1060. PubMed ID: 35607780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.
    Ito K; Chapman R; Pearson SD; Tafazzoli A; Yaffe K; Gurwitz JH
    JAMA Netw Open; 2021 Oct; 4(10):e2129392. PubMed ID: 34677596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.
    Kosaner Kließ M; Martins R; Connolly MP
    J Prev Alzheimers Dis; 2021; 8(3):362-370. PubMed ID: 34101795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
    Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
    J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
    [No Abstract]   [Full Text] [Related]  

  • 10. The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial.
    Chiatti C; Furneri G; Rimland JM; Demma F; Bonfranceschi F; Cassetta L; Masera F; Cherubini A; Corsonello A; Lattanzio F;
    Int Psychogeriatr; 2015 Sep; 27(9):1563-72. PubMed ID: 25874654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Framework for Including Family Health Spillovers in Economic Evaluation.
    Al-Janabi H; van Exel J; Brouwer W; Coast J
    Med Decis Making; 2016 Feb; 36(2):176-86. PubMed ID: 26377370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD.
    Bhadhuri A; Al-Janabi H; Jowett S; Jolly K
    Int J Technol Assess Health Care; 2019 Jan; 35(3):212-220. PubMed ID: 31064563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.
    Krol M; Papenburg J; van Exel J
    Pharmacoeconomics; 2015 Feb; 33(2):123-35. PubMed ID: 25315368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden of Alzheimer's Disease Dementia in Japan.
    Ikeda S; Mimura M; Ikeda M; Wada-Isoe K; Azuma M; Inoue S; Tomita K
    J Alzheimers Dis; 2021; 81(1):309-319. PubMed ID: 33780371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic and societal burden of Alzheimer disease: managed care considerations.
    Skaria AP
    Am J Manag Care; 2022 Sep; 28(10 Suppl):S188-S196. PubMed ID: 36197132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial.
    Joling KJ; Bosmans JE; van Marwijk HW; van der Horst HE; Scheltens P; MacNeil Vroomen JL; van Hout HP
    Trials; 2013 Sep; 14():305. PubMed ID: 24053631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.